KDIGO 2025 ADPKD指南:ERA基因与肾脏工作组对肝胰表现的诊断与管理的评论
本文是对KDIGO 2025常染色体显性多囊肾病(ADPKD)指南中肝胰囊性表现相关推荐和实践要点的评论。ADPKD的肝囊肿多为影像学偶然发现,但囊肿感染和严重多囊肝病疾病负担高且管理困难;胰腺囊肿通常完全无症状但引发随访必要性的问题。评论旨在促进指南实施并指出指南、临床照护和研究中的空白。
要点
- ADPKD肝囊肿多为常规影像学偶然发现,但囊肿感染和严重多囊肝病疾病负担高且管理困难。
- ADPKD胰腺囊肿通常完全无症状,但引发是否需要随访的问题。
- ADPKD的系统性管理需跨学科协作,肾内科医生应关注肝胰等肾外表现。
核心结论
- KDIGO 2025 ADPKD指南是首个针对遗传性肾脏病的KDIGO指南,系统涵盖肾外表现管理。
- 本文评论肝胰囊肿相关推荐以促进实施并指出指南、临床照护和研究中的空白。
研究设计与样本
- 本文为对KDIGO 2025 ADPKD临床实践指南的评论,由ERA基因与肾脏工作组撰写。
主要发现
- ADPKD肝囊肿多为常规影像学偶然发现,但囊肿感染和严重多囊肝病疾病负担高且管理困难。
- ADPKD胰腺囊肿通常完全无症状,但引发随访必要性的问题。
临床怎么用
- ADPKD肾外表现的管理需跨学科协作。
- 肾内科医生应关注肝胰囊肿的评估与管理。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The Kidney Disease Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a long-awaited development and the first KDIGO guideline addressing a genetic kidney disease. The approval of tolvaptan as targeted therapy for ADPKD in 2015 marked a pivotal advancement and motivated a structured approach in research and clinical care. The systemic nature of ADPKD guidance for the management of extrarenal manifestations is of special importance for nephrologists and requires interdisciplinary collaboration. In this regard, cysts in other organs, particularly the liver, are the most common extrarenal finding. While most liver cysts are incidental findings on routine imaging, both cyst infections and severe polycystic liver disease accompanying ADPKD come with a high disease burden and challenges in management. In contrast, pancreatic cysts in ADPKD are usually completely asymptomatic, but this raises questions about the need for follow-up. This commentary provides an overview of the most important recommendations and practice points on hepatopancreatic cysts provided by the KDIGO guideline with the aim to contribute to implementation and highlight remaining gaps in guidance, clinical care and research.
引用
- Müller RU, Cornec-Le Gall E, Degenhardt J, et al. KDIGO 2025 ADPKD guideline: a commentary on diagnosis and management of hepatopancreatic manifestations by the ERA Working Group Genes & Kidney. Nephrol Dial Transplant. 2025. PMID: 40810467. doi:10.1093/ndt/gfaf159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。